Full integration of digital breast tomosynthesis reduces false positive rates, study shows

February 12, 2018, American Roentgen Ray Society

Rates of false positive breast cancer screening exams fell significantly after complete integration of diagnostic digital breast tomosynthesis (DBT), potentially leading to higher quality, lower costs, and fewer unnecessary biopsies, according to a study to be presented at the ARRS 2018 Annual Meeting, set for April 22-27 in Washington, DC.

DBT is associated with fewer false positive exams in the screening setting, but there is limited research on the impact of DBT on false positive exams in the diagnostic setting. The study, to be presented by Charmi Vijapura of Harvard University's Massachusetts General Hospital, compared the rates of false positive exams between digital 2D mammography (DM) and DBT in the diagnostic setting in order to determine if there are differences in the mammographic findings that lead to false positive exams.

The study compared consecutive diagnostic mammograms from August 2008 to February 2011, which utilized DM, prior to DBT integration, and from January 2013 to July 2015, after complete DBT integration. Mammograms were considered false-positive exams if there was no known tissue diagnosis of within one year after recommendation for tissue diagnosis or surgical consultation on the basis of a positive .

The results showed the cancer-detection rate was significantly higher in the DBT group than the DM group, and the false-positive rate was significantly lower in the DBT group compared with the DM group.

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2018 Annual Meeting, April 22-27, at the Marriott Wardman Park Hotel in Washington, DC.

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2018 Annual Meeting, April 22–27, at the Marriott Wardman Park Hotel in Washington, DC. For more information, visit: www.arrs.org/am18 .

Explore further: Including diagnosis related costs, 3-D mammography costs less than digital mammography

Related Stories

Including diagnosis related costs, 3-D mammography costs less than digital mammography

December 8, 2017
Although digital breast tomosynthesis (DBT), or 3-D mammography, costs more than a digital mammography (DM) screening, it actually may help rein in cancer screening costs, according to preliminary findings (PD7-05) presented ...

Women prefer getting mammograms every year

November 21, 2017
Women prefer to get their mammograms every year, instead of every two years, according to a new study being presented next week at the annual meeting of the Radiological Society of North America (RSNA).

3-D imaging improves breast cancer screening

November 9, 2016
What if breast cancers could be found earlier, lumps seen more clearly or the number of callbacks reduced? Three-dimensional breast imaging technology can do just that by increasing the accuracy of breast cancer screening ...

Novel breast screening technology increases diagnostic accuracy

November 20, 2012
The addition of three-dimensional breast imaging—a technology called tomosynthesis—to standard digital mammography significantly increases radiologists' diagnostic accuracy while reducing false positive recall rates, ...

Mammo outcomes improve when docs compare prior screenings

November 3, 2016
The recall rate of screening mammography is reduced when radiologists compare with more than one prior mammogram, a study published in the October 2016 issue of the American Journal of Roentgenology said.

Recommended for you

Solving the mystery of NPM1 in acute myeloid leukemia

November 13, 2018
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

Study finds promising therapeutic target for aggressive type of breast cancer

November 13, 2018
A new Nature Communications study led by University of Kentucky Markey Cancer Center researchers suggests that an enzyme known as Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) is a potential therapeutic target for triple negative ...

Scientists shine new light on link between obesity and cancer

November 12, 2018
Scientists have made a major discovery that shines a new, explanatory light on the link between obesity and cancer. Their research confirms why the body's immune surveillance systems—led by cancer-fighting Natural Killer ...

Obesity both feeds tumors and helps immunotherapy kill cancer

November 12, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.

Two-pronged device enables maverick immune cells to identify and kill cancers

November 12, 2018
Immune cells called Gamma Delta T cells can act independently to identify and kill cancer cells, defying the conventional view of the immune system, reveals new research from the Francis Crick Institute and King's College ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.